Double-blind, randomised 2×2 crossover study in healthy adults (n=22) testing IV Delta-9-THC (0.015 mg/kg) and IV ketamine (0.2 mg/kg) alone and combined with EEG and psychotomimetic outcomes.
Healthy volunteers receive IV Delta-9-THC (0.015 mg/kg) and IV ketamine (0.2 mg/kg) in a double-blind, randomized 2×2 crossover; each session pairs THC (active or placebo) followed by ketamine (active or placebo).
Primary outcomes include EEG measures of neural oscillations during peak drug effects and psychotomimetic/cognitive assessments to probe CB1R and NMDAR contributions to psychosis-like phenomena.
Active IV Delta-9-THC and placebo IV ketamine (one combination condition of the 2×2 crossover).
Active Delta-9-THC 0.015 mg/kg IV
Placebo ketamine IV
Active IV Delta-9-THC and active IV ketamine (one combination condition of the 2×2 crossover).
Active Delta-9-THC 0.015 mg/kg IV
Active ketamine 0.2 mg/kg IV
Placebo IV Delta-9-THC and placebo IV ketamine (control condition).
Placebo Delta-9-THC IV
Placebo ketamine IV
Placebo IV Delta-9-THC and active IV ketamine (one combination condition of the 2×2 crossover).
Placebo Delta-9-THC IV
Active ketamine 0.2 mg/kg IV